Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05275374 |
| Title | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) |
| Acronym | ENHANCE |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Xynomic Pharmaceuticals, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries |
CKB BOOST